Prototype vaginal gel fails to block HIV: study

September 20, 2010

A vaginal gel failed to protect women against the AIDS virus, doctors said on Monday, reporting on a major clinical trial that enrolled more than 9,000 women.

The formula, known as PRO 2000, was tested in a Phase III trial, the widest and most exhaustive stage of the process to assess a new drug for safety and effectiveness.

AIDS campaigners have staked huge faith in the search for a vaginally-used gel to thwart the (HIV). It would revolutionise the fight on AIDS by empowering women, especially in African countries where coercive sex is a problem.

The first breakthrough in this quest was announced in July at the 18th International AIDS Conference in Vienna.

Scientists reported that a cream tested in a Phase IIb trial in South Africa called CAPRISA 004 cut the risk of by 39 percent overall, and by 54 percent among those women who used it most consistently.

This level of protection may not be enough to make the CAPRISA gel get approval, however.

The cream incorporates tenofovir, a drug commonly used in tablet form to quell HIV by disrupting its reproduction in .

The PRO 2000 formula is different, being a so-called large charged polymer, which is intended to disrupt HIV's interaction with targeted cells.

It was tested at two levels of concentration, of two percent and 0.5 percent, in 13 clinics in South Africa, Tanzania, Uganda and Zambia in a trial that was closely monitored for ethical standards.

Volunteers were women who were aged 18 years or older, were sexually active and did not have HIV. They were given either the gel or an inactive dummy cream called a placebo. All were given counselling on and access to condoms.

Their HIV status was then tested at 12 weeks, 24 weeks, 40 weeks and 52 weeks after starting with the product.

PRO 2000 was found to be safe but ineffective, according to the report card, published online by The Lancet.

"Safety-related events were rare and at similar rates in all three groups... (but) HIV-1 incidence was much the same between groups at study end," it said.

In an important detail, use of the gel -- a big challenge in microbicides -- was high. Eighty-nine percent of the women said they used it prior to intercourse.

Twenty-five million people have been killed by AIDS and more than 33 million others today are infected by , which causes the disease.

More than two-thirds of these live in sub-Saharan Africa, where 60 percent of the estimated 1.9 million new infections in 2008 occurred among women and girls.

Related Stories

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

6 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

dtxx
5 / 5 (1) Sep 20, 2010
Doctor 1: "How many women were in the study?"
Doctor 2: "IT'S OVER 9000!"
genastropsychicallst
Sep 20, 2010
This comment has been removed by a moderator.
genastropsychicallst
1 / 5 (1) Sep 20, 2010
... toggle WebStat on my site, about type proto ...
abzu
4.5 / 5 (2) Sep 20, 2010
"Thank you for participating; you now have HIV. Please take this coffee mug and tshirt for your time here."
trekgeek1
not rated yet Sep 20, 2010
Doctor 1: "How many women were in the study?"
Doctor 2: "IT'S OVER 9000!"


Okay, I looked that up and I see that it was in fact a brilliant cultural reference. Kudos.
ArtflDgr
5 / 5 (1) Sep 20, 2010
Given the penis is shaped for reasons of female infidelity, its pretty nigh hard to get anything like that to work, since the whole of it is to remove previous jelly like material, and replace it with the new jelly like material... (called semen)

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.